Abstract
Summary: A number of presentations focused on immunotherapy of bronchogenic cancer were also presented at this year's ASCO virtual conference. In non-small cell lung cancer (NSCLC), its progression to lower stages of the disease is clearly evident.
The results of studies in which immunotherapy was administered as neoadjuvant or adjuvant treatment in resectable NSCLC were presented. In metastatic NSCLC, a combination of immunotherapy and chemotherapy confirms its effectiveness.
With the increasing results of studies with targeted treatment, treatment options focused on proven genetic aberrations are further expanding.